Literature DB >> 16302262

Prostate cell lines secrete IL-8 in response to Mycoplasma hominis through Toll-like receptor 2-mediated mechanism.

Koh Takeyama1, Hiroaki Mitsuzawa, Takeyuki Shimizu, Masanori Konishi, Chiaki Nishitani, Hitomi Sano, Yasuharu Kunishima, Masanori Matsukawa, Satoshi Takahashi, Ken-Ichiro Shibata, Taiji Tsukamoto, Yoshio Kuroki.   

Abstract

BACKGROUND: The roles of Toll-like receptor 2 (TLR2) and Mycoplasma in prostate inflammation remain unclear. We investigated whether Mycoplasma induced inflammatory cytokine secretion through TLR2-mediated mechanism in prostate cancer cell line.
METHODS: Cell surface expression of TLR2 on PC-3 cells were examined by flowcytometry. PC-3 cells were stimulated with Mycoplasma hominis (M. hominis), and IL-8 secretion and NF-kappaB activation were examined.
RESULTS: PC-3 cells expressed TLR2 mRNA and cell surface TLR2 protein. The membrane fraction of M. hominis induced IL-8 secretion from PC-3 cells and NF-kappaB activation in a concentration-dependent manner. Transient transfection of the dominant negative mutant TLR2(P681H) into PC-3 cells attenuated M. hominis-induced IL-8 secretion and NF-kappaB activation. Antibody against the extracellular TLR2 domain significantly suppressed M. homnis-induced IL-8 secretion from the prostate cell lines including PC-3, PrEC, and transformed myofibroblasts.
CONCLUSIONS: These results clearly demonstrate that the prostate cell line can secrete inflammatory cytokine in response to M. hominis through a TLR2-mediated mechanism. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16302262     DOI: 10.1002/pros.20358

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Propionibacterium acnes infection induces upregulation of inflammatory genes and cytokine secretion in prostate epithelial cells.

Authors:  Johanna B Drott; Oleg Alexeyev; Patrik Bergström; Fredrik Elgh; Jan Olsson
Journal:  BMC Microbiol       Date:  2010-04-26       Impact factor: 3.605

2.  Bacterial modulation of human fetal membrane Toll-like receptor expression.

Authors:  Vikki M Abrahams; Julie A Potter; Geeta Bhat; Morgan R Peltier; George Saade; Ramkumar Menon
Journal:  Am J Reprod Immunol       Date:  2012-09-11       Impact factor: 3.886

3.  Serum antibodies against genitourinary infectious agents in prostate cancer and benign prostate hyperplasia patients: a case-control study.

Authors:  Jan Hrbacek; Michael Urban; Eva Hamsikova; Ruth Tachezy; Vaclav Eis; Marek Brabec; Jiri Heracek
Journal:  BMC Cancer       Date:  2011-02-03       Impact factor: 4.430

4.  Decreased expression of Toll-like receptor 4 and 5 during progression of prostate transformation in transgenic adenocarcinoma of mouse prostate mice.

Authors:  Ju-Hee Han; Jong-Hwan Park; Bo-Yeon Kim; Seo-Na Chang; Tae-Hyoun Kim; Jae-Hak Park; Dong-Jae Kim
Journal:  J Vet Sci       Date:  2015-03-20       Impact factor: 1.672

Review 5.  Toll-Like Receptor 2 at the Crossroad between Cancer Cells, the Immune System, and the Microbiota.

Authors:  Antonino Di Lorenzo; Elisabetta Bolli; Lidia Tarone; Federica Cavallo; Laura Conti
Journal:  Int J Mol Sci       Date:  2020-12-10       Impact factor: 5.923

6.  Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.

Authors:  Rajendra K Singh; Bal L Lokeshwar
Journal:  Mol Cancer       Date:  2009-07-31       Impact factor: 27.401

7.  The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation.

Authors:  Simin Rezania; Noor Amirmozaffari; Nesa Rashidi; Ebrahim Mirzadegan; Saeed Zarei; Jamileh Ghasemi; Omid Zarei; Leila Katouzian; Amir-Hassan Zarnani
Journal:  Cancer Cell Int       Date:  2014-06-19       Impact factor: 5.722

Review 8.  Toll-like receptors in prostate infection and cancer between bench and bedside.

Authors:  Guido Gambara; Paola De Cesaris; Cosimo De Nunzio; Elio Ziparo; Andrea Tubaro; Antonio Filippini; Anna Riccioli
Journal:  J Cell Mol Med       Date:  2013-04-04       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.